"We talk about the S-curve for technology and in the past we've said it can be 10 or 20 years before you reach the top. I think what's going to be really different about AI is that time frame is going ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor ...

GSK PLC closed 23.91% below its 52-week high of £18.24, which the company reached on May 16th.

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

Pharmaceutical giant GSK and the University of Oxford are collaborating on developing a cancer vaccine that aims to detect ...

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of p1,580.00. The ...

Sheryl Lee Ralph exclusively told Us Weekly she is ready to reunite with Denzel Washington for an 'adult rom-com' ...

Shares of GSK PLC GSK inched up 0.94% to £14.01 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising 0.28% to 8,557.81. GSK ...

GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the Marketing Authorisation Application, MAA, for the use of depemokimab in two indications. The submitted indicati ...

We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...

GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here ...